S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
Big banks warn of uncertain year ahead after mixed financial performances in the first quarter
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
Big banks warn of uncertain year ahead after mixed financial performances in the first quarter
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
Big banks warn of uncertain year ahead after mixed financial performances in the first quarter
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
Big banks warn of uncertain year ahead after mixed financial performances in the first quarter
NASDAQ:APGN

Apexigen (APGN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.39
$0.39
50-Day Range
$0.36
$0.44
52-Week Range
$0.33
$8.28
Volume
N/A
Average Volume
967,731 shs
Market Capitalization
$9.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
APGN stock logo

About Apexigen Stock (NASDAQ:APGN)

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.

APGN Stock News Headlines

This tech is sneaking up on Americans’ portfolios
Most Americans have zero idea how advanced A.I. has gotten. To them, it’s still a simple little chatbot that works like a really good version of Google. What they don’t realize is that it is becoming the go-to competitive advantage for people who are serious about their financial well-being. Whether it’s improving productivity at work, replacing employees in their business… or outperforming in the markets. A.I. grants the competitive advantage necessary to get ahead in this economy. It’s become the digital edge that can deliver solid returns… consistently.
APG SGA S.A.
This tech is sneaking up on Americans’ portfolios
Most Americans have zero idea how advanced A.I. has gotten. To them, it’s still a simple little chatbot that works like a really good version of Google. What they don’t realize is that it is becoming the go-to competitive advantage for people who are serious about their financial well-being. Whether it’s improving productivity at work, replacing employees in their business… or outperforming in the markets. A.I. grants the competitive advantage necessary to get ahead in this economy. It’s become the digital edge that can deliver solid returns… consistently.
Apexigen, Inc. (APGN)
See More Headlines
Receive APGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apexigen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APGN
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Net Income
$-32,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.09) per share

Miscellaneous

Free Float
20,088,000
Market Cap
$9.57 million
Optionable
Not Optionable
Beta
3.60
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Xiaodong Yang M.D. (Age 62)
    Ph.D., CEO & Director
    Comp: $532.99k
  • Mr. Francis W. Sarena (Age 52)
    Pres & COO
    Comp: $474.19k
  • Dr. Frank J. Hsu M.D. (Age 62)
    Chief Medical Officer
    Comp: $520.92k
  • Mr. William E. Duke Jr. (Age 51)
    Chief Financial Officer
  • Ms. Amy Wong (Age 57)
    Sr. VP of Fin. & Operations
  • Dr. Jason Wright Ph.D.
    Sr. VP of CMC

This page (NASDAQ:APGN) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners